Secondary analysis (median 2.2 years) of a phase 3 trial in newly diagnosed chronic-phase CML: week-96 major molecular response 74.1% with asciminib vs 52.0% with investigator-selected TKIs, and 76.2% vs 47.1% vs imatinib; fewer AE-related stops.
Secondary analysis
Cortes et al. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial